Sign In
Buy ABT
$90.53
+2.76 (+3.14%)
At Close: Jun 23, 2026
Abbott Hedges Grid Bets As EU Advances Controversial Green Investment Plan
10:23am, Wednesday, 02'nd Feb 2022
Texas Governor Greg Abbott warned Texans that he could not guarantee they would not lose power in a looming winter storm, as officials at the EU advanced a plan to qualify nuclear and natural gas powe
USD 2.34 Bn growth expected in Vitamin D Market | Driven by increasing awareness about vitamin D importance | Technavio
01:00am, Tuesday, 01'st Feb 2022 Kwhen FinanceEaton Vance Worldwide Health Sciences Fund Dumps Medtronic, Boosts Abbott Labs
03:33pm, Friday, 28'th Jan 2022
The Eaton Vance Worldwide Health Sciences Fund (Trades, Portfolio) disclosed its portfolio for the fourth quarter of 2021 earlier this week.
Fridays Top Analyst Upgrades and Downgrades: Abbott Laboratories, ArcelorMittal, AT&T, Chewy, Clean Energy Fuels, Fisker, Freeport-McMoRan, Intel, Las Vegas Sands, Lennar, Marathon Digital, Pag Seguro Digital, Seagate Technology, Twilio, Walmartand More
01:59pm, Friday, 28'th Jan 2022 24/7 Wall street
Friday''s top analyst upgrades and downgrades included Abbott Laboratories, ArcelorMittal, AT&T, Chewy, Clean Energy Fuels, Fisker, Freeport-McMoRan, Intel, Las Vegas Sands, Lennar, Marathon Digital, Pag Seguro Digital, Seagate Technology, Twilio and Walmart.
5 Top Health Care Stocks To Watch Before February 2022
02:30pm, Thursday, 27'th Jan 2022
Should investors be paying more attention to these health care stocks?
Abbott Lab's Sales Jumped 24.5% in 2021
11:28am, Thursday, 27'th Jan 2022
On Wednesday, Abbott Laboratories ( ABT , Financial) reported its earnings results for the fourth quarter and full year of 2021.
Institutions Cap Gains In Abbot Laboratories
01:00am, Thursday, 27'th Jan 2022
As has become the theme of 1st quarter trading, it looks like institutional activity capped the gains in Abbot Laboratories (NYSE: ABT) but the bottom may already be in sight for shareholders. While t
Abbott Laboratories (ABT) CEO Robert Ford on Q4 2021 Results - Earnings Call Transcript
05:36pm, Wednesday, 26'th Jan 2022 Seeking AlphaAnnual Forecast Weighs On Healthcare Name
02:34pm, Wednesday, 26'th Jan 2022
Abbot Laboratories (ABT) announced better-than-expected fourth-quarter earnings results ahead of the open today.
Abbott Posts $2.3B In COVID-19 Test Sales In Q4; Issues FY22 Outlook
01:39pm, Wednesday, 26'th Jan 2022 Benzinga
Abbott Laboratories (NYSE: ABT ) has reported Q4 FY21 adjusted EPS of $1.32 , down from $1.45 a year ago but better than the consensus of $1.21. Q4 sales of $11.5 billion increased 7.2% on a reported basis and 7.7% on an organic basis, beating the consensus of Full story available on Benzinga.com
Cramer's Investing Club: We believe the market is wrong on core holding Abbott's future potential
01:02pm, Wednesday, 26'th Jan 2022
Abbott management, known for under promising and over delivering, will do better than Wall Street thinks.
Abbott sales rise 7.2% as COVID test demand surges
12:49pm, Wednesday, 26'th Jan 2022 Reuters
Abbott Laboratories on Wednesday reported a 7.2% rise in quarterly sales on strong demand for diagnostics products, including its COVID-19 tests, led by a sharp surge in cases due to the Omicron variant.
Abbott posts $2.3 billion in quarterly COVID test sales
12:38pm, Wednesday, 26'th Jan 2022 FX Empire
(Reuters) Abbott Laboratories reported $2.3 billion in COVID-19 test sales for the fourth quarter, majority of which were rapid test kits, tracking a sharp surge in cases led by the Omicron variant.
Abbott Laboratories (ABT) CEO Robert Ford on Q4 2021 Results - Earnings Call Transcript
12:36pm, Wednesday, 26'th Jan 2022
Abbott Laboratories (ABT) CEO Robert Ford on Q4 2021 Results - Earnings Call Transcript
Abbott Laboratories Non-GAAP EPS of $1.32 beats by $0.11, revenue of $11.5B beats by $790M (NYSE:ABT)
12:31pm, Wednesday, 26'th Jan 2022 Seeking Alpha
Abbott Laboratories press release (ABT): Q4 Non-GAAP EPS of $1.32 beats by $0.11.Revenue of $11.5B (+7.5% Y/Y) beats by $790M.Shares +1.1% PM.Abbott issues full-year 2022 guidance
